223 related articles for article (PubMed ID: 16599026)
1. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
Ayyub M; Ali W; Anwar M; Waqar A; Khan MN; Ijaz A; Hussain T; Hussain S
J Ayub Med Coll Abbottabad; 2005; 17(4):12-5. PubMed ID: 16599026
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
3. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
Mazza P; Amurri B; Lazzari G; Masi C; Palazzo G; Spartera MA; Giua R; Sebastio AM; Suma V; De Marco S; Semeraro F; Moscogiuri R
Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
[TBL] [Abstract][Full Text] [Related]
4. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
5. Oral iron chelation therapy with deferiprone in patients with Thalassemia Major.
Sajid R; Ghani F; Adil S; Khurshid M
J Pak Med Assoc; 2009 Jun; 59(6):388-90. PubMed ID: 19534375
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
9. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
Mirbehbahani N; Jahazi A; Rahim Abad HH
Hematology; 2012 May; 17(3):183-6. PubMed ID: 22664119
[TBL] [Abstract][Full Text] [Related]
10. Iron chelation therapy.
Hoffbrand AV; Wonke B
J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study.
Taher A; Sheikh-Taha M; Sharara A; Inati A; Koussa S; Ellis G; Dhillon AP; Hoffbrand AV
Acta Haematol; 2005; 114(3):146-9. PubMed ID: 16227677
[TBL] [Abstract][Full Text] [Related]
12. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
13. Combined oral and parenteral iron chelation in beta thalassaemia major.
Balveer K; Pyar K; Wonke B
Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
[TBL] [Abstract][Full Text] [Related]
14. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with deferiprone in a L1 veteran.
Meo A; Ruggeri A; La Rosa MA; Zanghì L; Kordes U; Fischer R
Eur J Haematol; 2005 Jun; 74(6):523-5. PubMed ID: 15876257
[TBL] [Abstract][Full Text] [Related]
16. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
[TBL] [Abstract][Full Text] [Related]
17. Deferiprone chelation therapy for thalassemia major.
Galanello R; Campus S
Acta Haematol; 2009; 122(2-3):155-64. PubMed ID: 19907153
[TBL] [Abstract][Full Text] [Related]
18. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
Cermak J; Jonasova A; Vondrakova J; Walterova L; Hochova I; Siskova M; Neuwirtova R
Hemoglobin; 2011; 35(3):217-27. PubMed ID: 21599434
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
Agarwal MB; Gupte SS; Vasandani D; Viswanathan C; Puniyani RR; Ramanathan J; Massil DE; Shah S; Rajyadhyaksha GC; Bhave AA
J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
